Assessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial.
Eur J CancerSep 16, 2026 (epub)
Clinical ResearchOncology (Medical)
Yuan Liu, Marta Fiocco, Laura Kirton et al.
✦ AI-curated · Sources linked
In 30 seconds
This retrospective analysis of the Euro Ewing 2012 trial evaluated the impact of chemotherapy dose reductions and time delays on event-free survival (EFS) in Ewing Sarcoma patients. The study found that dose reduction was associated with a protective effect on EFS (HR=0.69), while time delay had a slightly detrimental effect (HR=1.02), though both results were non-statistically significant.
Key findings
- Dose reduction was associated with a protective effect on EFS (HR=0.69; 95%CI: [0.39; 1.24]).
- Time delay showed a slightly detrimental effect on EFS (HR=1.02; 95%CI: [0.90; 1.15]).
- No significant detrimental effect on EFS was found from treatment adjustments for toxicity management.
Why it matters
Understanding the effects of chemotherapy dose adjustments and delays is crucial for optimizing treatment protocols in Ewing Sarcoma, ensuring that patient safety is prioritized without compromising survival outcomes.